Your shopping cart is currently empty

AF3485, a human mPGES-1 inhibitor, exhibits anti-tumor activity both in vitro and in vivo. It achieves this by reducing PGE2 production, inhibiting EGFR signaling, and decreasing the expression of VEGF and FGF-2, which suppresses tumor-associated angiogenesis. When subchronically administered to mice with human A431 xenograft tumors, AF3485 effectively curtails tumor growth.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks | 6-8 weeks |
| Description | AF3485, a human mPGES-1 inhibitor, exhibits anti-tumor activity both in vitro and in vivo. It achieves this by reducing PGE2 production, inhibiting EGFR signaling, and decreasing the expression of VEGF and FGF-2, which suppresses tumor-associated angiogenesis. When subchronically administered to mice with human A431 xenograft tumors, AF3485 effectively curtails tumor growth. |
| Molecular Weight | 398.38 |
| Formula | C22H17F3N2O2 |
| Cas No. | 1195786-61-8 |
| Smiles | O=C(NC1=CC=C2C(=C1)C=3C=CC=CC3N2CCO)C=4C=CC=CC4C(F)(F)F |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.